General information, not medical advice. BPC-157 and TB-500 are not FDA-approved. Medical disclaimer · Editorial policy

LEGAL

BPC-157 and TB-500 for Sale? What FDA Status Means

By the BPC-TB Guide editorial team · Last updated October 9, 2026 · 9 min read

Abstract graphic of a closed gate in red-orange and gray at the end of three converging paths, with a date tag beside it

Quick answer: There is no FDA-approved BPC-157 or TB-500 product to point you to. No FDA-approved drug contains BPC-157 or TB-500 as of 2026-10-09, and neither is on the 503A bulks list that a pharmacy would need for a prescription route. FDA's page, current as of 2026-04-22, lists both as "nominated but withdrawn". This page links to no seller and explains the status instead.

People who search "where to buy BPC-157 and TB-500" usually want a source they can trust. The honest answer is that this is the wrong question until the legal status changes: there is no approved product, no established prescription route under current rules, and the online products that do exist are sold under wording FDA has challenged. We name no seller and no clinic, and we link to none.

  • Approved product

    None. No FDA-approved drug contains BPC-157 or TB-500 (as of 2026-10-09)

  • FDA

    Both listed as "nominated but withdrawn"; advisory meeting held 2026-07-23; no final decision found (as of 2026-10-09)

  • WADA

    BPC-157 in S0 and TB-500 in S2.3 of the 2026 List (as of 2026-10-09)

  • Human trials

    No human TB-500 study found by FDA; BPC-157 has a few small, short studies per FDA's briefing (as of 2026-10-09)

Status: what "no approved product" means

An approved drug has a label that states its use, strength, ingredients and warnings, and FDA has reviewed the manufacturing. For neither substance is there such a drug. FDA's July 2026 briefing documents say each has no United States Pharmacopeia monograph and neither is a component of an FDA-approved drug. We searched DailyMed and Drugs@FDA on 2026-10-09 for the names and found nothing. The full regulator-by-regulator table is on the legal status page.

For the research behind each name, see the TB-500 page and the BPC-157 page. FDA's TB-500 briefing says it found no articles in which TB-500 was given to humans, and that potential safety risks in humans "are unknown". For BPC-157 it found five small, short clinical studies and called the safety information limited.

Why a prescription route does not exist right now

A prescription route normally means a pharmacy compounds a drug for one patient. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a compounder keeps the law's exemptions only when bulk substances meet one of three conditions: an applicable USP or NF monograph exists; if none exists, the substance is a component of an approved drug; or, if neither applies, the substance appears on a list the Secretary develops "through regulations". FDA's pages and briefings (read 2026-10-09) say BPC-157 and TB-500 have no monograph and are in no approved drug. That leaves the list. As of 2026-10-09, FDA's meeting page describes both as "being considered for inclusion on the 503A Bulks List", which indicates neither is on it yet, and under the statute text the exemption conditions are met only if the list condition is.

Two more facts matter. First, being "nominated but withdrawn" is not a placement on the list. FDA's bulk-substance overview page (current as of 2026-05-14) says the agency does not intend to act against compounding with category 1 substances under its interim policy; it does not extend that statement to other substances, and law-firm commentary applies that reading to these two names, which is an attributed reading and not FDA's own sentence about them. Second, FDA's data in its BPC-157 briefing showed no reported compounded BPC-157 products from outsourcing facilities between January 2017 and June 2025, and its TB-500 briefing found no pharmacies marketing compounded TB-500 at the time of review.

Abstract flowchart with three conditions ending at a single closed gate marked list, in red-orange and gray

What a pending advisory vote would and would not change

An FDA advisory committee met on 2026-07-23 about whether to add BPC-157 and TB-500 to the 503A bulks list. News outlets reported a narrow vote in favor. FDA's meeting page, current as of 2026-08-06, posts briefings but no vote summary, and says committee recommendations are non-binding. FDA's own briefing documents for each substance say "we propose not adding" it to the list. As of 2026-10-09 we found no final FDA decision.

If FDA did add a substance, here is what that would and would not do, based on the statute text and FDA's process pages:

  • It would, through a rule, create a list condition that 503A pharmacies could rely on for an identified patient with a prescription.
  • It would not make the substance an approved drug, and it would not tell anyone the compound works. FDA's briefings found little human data on either.
  • It would not change the status of products sold online under other wording.
  • It would not change WADA's List, which has its own process.

Until a rule exists, we cannot tell you how a future route would look. Check FDA's meeting page and the Federal Register rather than a seller's page, because sellers have a reason to describe the status favorably.

What clinics advertising it may be describing

We cannot verify what any particular clinic dispenses, and we do not name any. A clinic page that mentions BPC-157 or TB-500 could be describing one of several things, and the page often does not say which:

  • a different, FDA-approved drug, with the peptide named only as marketing background;
  • a compounded product whose bulk-substance source and compliance with section 503A cannot be checked from the page;
  • a product that carries "research use only" wording, which FDA says does not change intended use when the marketing shows human use (see the label explainer);
  • a product in a registered study, which would be listed on ClinicalTrials.gov.

On the last point: as of 2026-10-09 ClinicalTrials.gov lists four records for BPC-157, none with posted results. A registry listing alone is not proof of a real, completed study, so check the record's status and results.

A health publisher's page, dated 2026-08-03, says the peptides are "newly approved for compounding". FDA's pages say no such thing, and we read that line as the publisher's, not as FDA's. When any page makes a status claim, look for a regulator's name and a date. The clinic questions and the sourcing questions are the same: which substance, from which supplier, under which legal basis, with what test results. See how to read a label and certificate of analysis for what those documents can and cannot prove.

What FDA says about products marketed online

FDA's BPC-157 briefing notes websites selling BPC-157 and TB-500 combination products "for research purposes only and not for human or veterinary use". The same briefing says BPC-157 "is marketed in the United States as an ingredient in dietary supplement products" and does not address whether those sales are lawful, so we make no statement on that. FDA's warning letters, ten of which we read from 2025-02-26 to 2026-08-24, say a research-use-only label does not change the products' intended use when the seller's marketing shows human use. None of the ten names these two substances; one from 2023-06-12 does.

FDA's compounding questions page (current as of 2025-09-16) says compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness or quality before they are marketed. It also encourages consumers to research an online pharmacy. FDA's personal-importation page (current as of 2025-08-18) adds that a person cannot import an unapproved new drug and that personal-use imports are usually unlawful.

Risks FDA and others describe

FDA's pages cite immunogenicity, meaning an immune reaction, for peptides given by certain routes, plus risks from aggregation and peptide-related impurities. FDA's BPC-157 briefing reports three adverse-event reports through 2025-12-04: injection-site redness and swelling confounded by other injectables, shortness of breath with an emergency visit, and skin and gum darkening linked to a product labeled for research purposes only that combined BPC-157 and TB-500. FDA says those reports alone cannot support definitive safety conclusions. The 2026 Missouri Medicine review (PMID 42757290) names contamination, impurities from manufacturing and dosing inaccuracy as severe potential risks. For the documented effects, see the side-effects page; for how blends are labeled, see the blend page; and for the Wolverine nickname, see the stack page. The homepage lists every guide.

Sources

FAQ

Is there a legal way to get BPC-157 or TB-500?

We found no established route under current rules as of 2026-10-09. No approved product exists, and neither substance is on the 503A bulks list. We give no legal conclusion; ask a licensed attorney or pharmacist.

Does a prescription make it legal?

A prescription does not change a substance's status. Under the statute text, a pharmacy needs a monograph, an approved-drug component or a list condition, and FDA's pages say the first two do not apply here.

What if a clinic says it offers it?

We cannot verify any clinic's claim. Ask which substance, which supplier and which legal basis, and compare the answer with FDA's pages. The section above lists what such a page may be describing.

Will the advisory vote change this?

A committee vote is non-binding, and as of 2026-10-09 we found no final FDA decision. A listing would require a rule and would not make either substance an approved drug.

Why do websites call them research chemicals?

FDA's briefing says some websites market them for research purposes only. FDA warning letters say that wording does not change intended use when marketing shows human use.

Where should I look for current status?

FDA's bulk-substance page, its advisory committee meeting page and the Federal Register, each of which shows a "content current" date.

Not medical advice. See the medical disclaimer.

More articles